Hemispherx Biopharma

Hemispherx Biopharma, Inc. has devoted nearly three decades to exploring, understanding, and mastering the mechanism of RNA technology. The Company's longevity as a biomedical research and drug development institution, coupled with its record of tremendous enduring scientific achievement is evidence of Hemispherx’s long-term commitment to this promising new class of drugs and to bring new therapeutic choices to the global community.



Using nucleic acid technologies to develop therapeutic products for the treatment of viral disease and certain cancers, the company has pioneered a new class of specifically-configured ribonucleic acid (RNA) which targets the treatment of Chronic Fatigue Syndrome (CFS), HIV associated disorders, chronic hepatitis B & C infection and cancers which include kidney cancer and metastatic malignant melanoma. Hemispherx with its predecessor, HEM Pharmaceuticals has nearly 30 years of RNA technology and is believed to be the only biotechnology company using nucleic acid drug methodology targeting the body's natural anti-viral defense system.

Contact Details: One Penn Center 1617 JFK Blvd., 6th Floor Philadelphia PA 19103 United States of America Tel: (215) 988-0080 Fax: (215) 988-1739 Email: info@hemispherx.net WWW: www.hemispherx.net/

Loading...

Recent Publications by Hemispherx Biopharma:
Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. In this multicenter, randomized, double-blind study the activity of...	29th March, 2000	Hemispherx Biopharma Incorporated, Philadelphia, Pennsylvania 19103, USA.	Eur J Clin Microbiol Infect Dis. 1996 Jul;15(7):580-7.

Press Releases on Hemispherx Biopharma:
GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN	11th June, 2009	GlobalEquityReport.com	BOSTON, June 11 /PRNewswire/ -- GlobalEquityReport.com is pleased to offer its stock alerts service to the investing community. Investors who are interested in stocks on the move and in the news can
The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate	27th May, 2009	The Sage Group	CLINTON, N.J., May 27 /PRNewswire/ -- The Sage Group, a privately held international health care consulting group, announced today that HemispherX Biopharma has expanded the mandate for The Sage Group
Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA	28th April, 2009	BeaconEquity.com	DALLAS, April 28 /PRNewswire/ -- BeaconEquity.com announces the availability of Stock Alerts on stocks making news today. As the influenza dominates the headlines, several biopharmaceutical stocks are

BioNews Results for Hemispherx Biopharma:
Brower Piven Encourages Investors Who Have Losses in Excess of	Ulitzer:  Nov 15 2009 1:15AM Matching: hemispherx biopharma
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 11, 2010 Lead Plaintiff Deadlin	Stockwatch:  Nov 14 2009 2:21PM Matching: hemispherx biopharma
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 11, 2010 Lead Plaintiff Deadlin	Earthtimes.org:  Nov 14 2009 2:17PM Matching: hemispherx biopharma
Brower Piven Files Class Action Lawsuit Against Hemispherx Biopharma - Quick Facts	RTTNews.com:  Nov 14 2009 8:52PM Matching: hemispherx biopharma
BUYINS.NET: Hemispherx Biopharma (HEB) Daily Short Sale Trading Volume Through 11-12-09. Over 23 Million Share	TradingMarkets:  Nov 13 2009 6:19PM Matching: hemispherx biopharma
Promote your company here: BioNewsCast - Press Release Distribution	→View more Hemispherx Biopharma news.

Hemispherx Biopharma Clinical Trials:
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Hemispherx Biopharma Patents:
US Patent No.	Title
5958718	Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
5763417	Protection from septic shock subsequent to injury by dsRNAs
5683986	Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
5593973	Treatment of viral hepatitis with mismatched dsRNA

Hemispherx Biopharma (HEB) Financial information Links from Barchart
HEB Quote from from Barchart.com
HEB Chart from from Barchart.com
HEB Profile from from Barchart.com
HEB Opinion from from Barchart.com
→View more Hemispherx Biopharma finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 499 times since April 2007, the link to the organisation's website has been followed 321 times

Recent Search Terms used to find this page: hemispherx biopharma march 2000 | hemispherx biopharma inc v johannesburg consolidated investments | mismatched double stranded rna aug 2009 | hemispherx | hemispherx biopharma inc. v. johannesburg consolidated investments | Hemispherx BioPharma Inc | hemispherx | hemispherx | hemispherx biopharma inc. v. johannesburg consolidated investments | hemispherx biopha | .

Search for more companies in Philadelphia

Search for more companies in PA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Hemispherx Biopharma